Daratumumab for post-ASCT maintenance treatment of myelomadoi:10.1016/S1470-2045(21)00490-3Prashant KapoorShaji KumarElsevier BVThe Lancet Oncology
Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma April 18th 2025 Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma April 15th 2025 Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Followi...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
When the study was designed, there was not as much informationavailable as there is now regarding the role of maintenance therapy in myeloma, the duration that maintenance should be offered, and the optimal dosing frequency schedule during ...
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.
MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma Author links open overlay panelMatthew Ho 1, Saurabh Zanwar 1, Prashant Kapoor 2, Morie Gertz 2, Martha Lacy 2, Angela Dispenzieri 2, ...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eli...
Latest Conference Coverage Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT ...
A supplemental biologics license application has been submitted to the FDA for the approval of daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autol